287 related articles for article (PubMed ID: 23160423)
21. Clinical perspectives of high-resolution mass spectrometry-based proteomics in neuroscience: exemplified in amyotrophic lateral sclerosis biomarker discovery research.
Ekegren T; Hanrieder J; Bergquist J
J Mass Spectrom; 2008 May; 43(5):559-71. PubMed ID: 18416436
[TBL] [Abstract][Full Text] [Related]
22. The biopharmaceutical industry and new drugs for amyotrophic lateral sclerosis.
Malta E
Adv Neurol; 1995; 68():263-9; discussion 271-5. PubMed ID: 8787239
[TBL] [Abstract][Full Text] [Related]
23. Sequential designs for clinical trials in amyotrophic lateral sclerosis.
Groeneveld GJ; van der Tweel I; Wokke JH; van den Berg LH
Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Dec; 5(4):202-7. PubMed ID: 15799547
[TBL] [Abstract][Full Text] [Related]
24. Protein biomarkers for amyotrophic lateral sclerosis.
Ryberg H; Bowser R
Expert Rev Proteomics; 2008 Apr; 5(2):249-62. PubMed ID: 18466055
[TBL] [Abstract][Full Text] [Related]
25. Can we eliminate placebo in ALS clinical Trials?
Simmons Z
Muscle Nerve; 2009 Jun; 39(6):861-5. PubMed ID: 19382170
[TBL] [Abstract][Full Text] [Related]
26. Amyotrophic Lateral Sclerosis, 2016: existing therapies and the ongoing search for neuroprotection.
Blasco H; Patin F; Andres CR; Corcia P; Gordon PH
Expert Opin Pharmacother; 2016 Aug; 17(12):1669-82. PubMed ID: 27356036
[TBL] [Abstract][Full Text] [Related]
27. Use of biomarkers in ALS drug development and clinical trials.
Bakkar N; Boehringer A; Bowser R
Brain Res; 2015 May; 1607():94-107. PubMed ID: 25452025
[TBL] [Abstract][Full Text] [Related]
28. Amyotrophic lateral sclerosis: a consensus viewpoint on designing and implementing a clinical trial.
Leigh PN; Swash M; Iwasaki Y; Ludolph A; Meininger V; Miller RG; Mitsumoto H; Shaw P; Tashiro K; Van Den Berg L
Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Jun; 5(2):84-98. PubMed ID: 15204010
[TBL] [Abstract][Full Text] [Related]
29. Increasing the efficiency of clinical trials in neurodegenerative disorders using group sequential trial designs.
van Eijk RPA; Nikolakopoulos S; Ferguson TA; Liu D; Eijkemans MJC; van den Berg LH
J Clin Epidemiol; 2018 Jun; 98():80-88. PubMed ID: 29486281
[TBL] [Abstract][Full Text] [Related]
30. Western ALS Study Group.
Miller RG; Moore DH; Jackson CE;
Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5 Suppl 1():121-4. PubMed ID: 15512892
[No Abstract] [Full Text] [Related]
31. [Minocycline for the treatment of amyotrophic lateral sclerosis: neuroprotector or neurotoxin? Reflections on another failure of translational medicine].
Gámez J
Neurologia; 2008 Oct; 23(8):484-93. PubMed ID: 18802797
[TBL] [Abstract][Full Text] [Related]
32. Clinical trials in ALS: an overview.
Turner MR; Parton MJ; Leigh PN
Semin Neurol; 2001 Jun; 21(2):167-75. PubMed ID: 11442325
[TBL] [Abstract][Full Text] [Related]
33. Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation.
Mead RJ; Shan N; Reiser HJ; Marshall F; Shaw PJ
Nat Rev Drug Discov; 2023 Mar; 22(3):185-212. PubMed ID: 36543887
[TBL] [Abstract][Full Text] [Related]
34. Neuroprotective agents for clinical trials in ALS: a systematic assessment.
Traynor BJ; Bruijn L; Conwit R; Beal F; O'Neill G; Fagan SC; Cudkowicz ME
Neurology; 2006 Jul; 67(1):20-7. PubMed ID: 16832072
[TBL] [Abstract][Full Text] [Related]
35. [Cell therapy in amyotrophic lateral sclerosis: science and controversy].
Galán L; Guerrero-Sola A; Gómez-Pinedo U; Matias-Guiu J
Neurologia; 2010 Oct; 25(8):467-9. PubMed ID: 20964996
[TBL] [Abstract][Full Text] [Related]
36. Assessment of disease progression and functional benefit in neurodegenerative disease: can we tell the difference?
Shefner JM; Mihaila D
Amyotroph Lateral Scler Frontotemporal Degener; 2014 Sep; 15(5-6):337-43. PubMed ID: 24918689
[TBL] [Abstract][Full Text] [Related]
37. [The advance in the research and therapeutic trials of amyotrophic lateral sclerosis].
Moriwaka F; Tashiro K
Rinsho Shinkeigaku; 2000 Dec; 40(12):1258-60. PubMed ID: 11464472
[TBL] [Abstract][Full Text] [Related]
38. ALS trial design: expectation and reality.
Miller RG; Moore DH
Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5 Suppl 1():52-4. PubMed ID: 15512873
[No Abstract] [Full Text] [Related]
39. High-throughput drug screens for amyotrophic lateral sclerosis drug discovery.
McGown A; Stopford MJ
Expert Opin Drug Discov; 2018 Nov; 13(11):1015-1025. PubMed ID: 30317895
[TBL] [Abstract][Full Text] [Related]
40. [What are the etiological medical therapies in amyotrophic lateral sclerosis?].
Dib M
Rev Neurol (Paris); 2006 Jun; 162 Spec No 2():4S215-4S219. PubMed ID: 17128114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
